Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Shunji Takahashi, Koji Matsumoto, Kojiro Ohba, Yasuhiro Nakano, Yasushi Miyazawa & Takumi Kawaguchi. (2023) The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancer Management and Research 15, pages 1033-1046.
Read now
Read now
Articles from other publishers (27)
Kaitlin R. McCarter, Senada Arabelovic, Xiaosong Wang, Taylor Wolfgang, Kazuki Yoshida, Grace Qian, Emily N. Kowalski, Kathleen M.M. Vanni, Nicole R. LeBoeuf, Elizabeth I. Buchbinder, Lydia Gedmintas, Lindsey A. MacFarlane, Deepak A. Rao, Nancy A. Shadick, Ellen M. Gravallese & Jeffrey A. Sparks. (2024) Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer. Seminars in Arthritis and Rheumatism 64, pages 152335.
Crossref
Crossref
Corinna Kochanek, Catharina Gilde, Lisa Zimmer, Selma Ugurel, Friedegund Meier, Jochen Utikal, Claudia Pföhler, Rudolf Herbst, Sebastian Haferkamp, Julia Welzel, Pia Dücker, Ulrike Leiter, Michael Weichenthal, Imke von Wasielewski, Yenny Angela & Ralf Gutzmer. (2024) Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG. European Journal of Cancer 198, pages 113508.
Crossref
Crossref
Nijiao Li, Xuliang Zheng, Jinyan Gan, Ting Zhuo, Xiaohong Li, Chuyi Yang, Yanbin WuShouming Qin. (2023) Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Chinese Medical Journal 136:21, pages 2562-2572.
Crossref
Crossref
A. D. Koltakova & A. M. Lila. (2023) Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem. Modern Rheumatology Journal 17:5, pages 112-117.
Crossref
Crossref
Rachel S. Goodman, Douglas B. Johnson & Justin M. Balko. (2023) Corticosteroids and Cancer Immunotherapy. Clinical Cancer Research 29:14, pages 2580-2587.
Crossref
Crossref
Shaked Lev‐Ari, Michael Serzan, Tianmin Wu, Andrew Ip, Lauren Pascual, Brittany Sinclaire, Shari Adams, Michael Marafelias, Lakshmi Ayyagari, Sarvarinder K. Gill, Barbara Ma, Jacob P. Zaemes, Alexandra Della Pia, Adil Alaoui, Subha Madhavan, Anas Belouali, Andrew Pecora, Jaeil Ahn, Michael B. Atkins & Neil J. Shah. (2023) The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study. Cancer 129:12, pages 1885-1894.
Crossref
Crossref
Javier García-Corbacho, Alberto Indacochea, Azucena E. González Navarro, Iván Victoria, Débora Moreno, David Pesántez, Laura Angelats, Andrea Modrego-Sanchez, Esther Sanfeliu, Oleguer Castillo, Paula Blasco, Laura Mezquita, Nuria Viñolas, Miquel Nogué, Patricia Galván, Barbara Adamo, Neus Basté, Tamara Sauri, Manel Juan, Aleix Prat & Francesco Schettini. (2023) Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study. Cancer Immunology, Immunotherapy 72:6, pages 1709-1723.
Crossref
Crossref
Stuti Khadka, Sara R. Druffner, Benjamin C. Duncan & Jonathan T. Busada. (2023) Glucocorticoid regulation of cancer development and progression. Frontiers in Endocrinology 14.
Crossref
Crossref
Peter Martin, Jonathon B. Cohen, Michael Wang, Anita Kumar, Brian Hill, Diego Villa, Jeffrey M. Switchenko, Brad Kahl, Kami Maddocks, Natalie S. Grover, Keqin Qi, Lori Parisi, Katherine Daly, Angeline Zhu & Gilles Salles. (2023) Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. Journal of Clinical Oncology 41:3, pages 541-554.
Crossref
Crossref
Cynthia Fournier, Ian Hirsch, Anna Spreafico, Marcus Otho Butler, Neesha Dhani & Maxwell Benjamin Sauder. (2023) Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature. SAGE Open Medical Case Reports 11.
Crossref
Crossref
Antongiulio Faggiano, Rossella Mazzilli, Annalisa Natalicchio, Valerio Adinolfi, Antonella Argentiero, Romano Danesi, Stella D’Oronzo, Stefano Fogli, Marco Gallo, Dario Giuffrida, Stefania Gori, Monica Montagnani, Alberto Ragni, Valerio Renzelli, Antonio Russo, Nicola Silvestris, Tindara Franchina, Enzo Tuveri, Saverio Cinieri, Annamaria Colao, Francesco Giorgino & Maria Chiara Zatelli. (2022) Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology 180, pages 103826.
Crossref
Crossref
Matthew Goldman, Brandon Lucke-Wold, Meleine Martinez-Sosa, Jason Katz, Yusuf Mehkri, Jeff Valisno & Stephan Quintin. (2022) Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies. Exploration of Targeted Anti-tumor Therapy, pages 659-675.
Crossref
Crossref
Hagai Ligumsky, Keren Merenbakh-Lamin, Noa Keren-Khadmy, Ido Wolf & Tami Rubinek. (2022) The role of α-klotho in human cancer: molecular and clinical aspects. Oncogene 41:40, pages 4487-4497.
Crossref
Crossref
Andrea De Giglio, Marta Aprile, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino & Andrea Ardizzoni. (2022) Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences 23:18, pages 10292.
Crossref
Crossref
Sebastian Bruera & Maria E. Suarez-Almazor. (2022) The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Frontiers in Oncology 12.
Crossref
Crossref
Gerasimos Eleftheriotis & Elias Skopelitis. (2022) Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report. Medicine 101:31, pages e29473.
Crossref
Crossref
Yixuan Yu, Yang Zhou, Xu Zhang, Kexin Tan, Jiabin Zheng, Jia Li & Huijuan Cui. (2022) Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. Frontiers in Oncology 12.
Crossref
Crossref
M. V. Verschueren, C. M. Cramer - van der Welle, M. Tonn, F. M. N. H. Schramel, B. J. M. Peters & E. M. W. van de Garde. (2021) The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC. Scientific Reports 11:1.
Crossref
Crossref
Peter D. Zang, Ramon O. Lee & Joshua A. Smith. (2021) Acute renal failure in patient with renal cell carcinoma after combination immune checkpoint inhibitor therapy. Current Problems in Cancer: Case Reports 4, pages 100082.
Crossref
Crossref
Jordan J. Baechle, David N. Hanna, Konjeti R. Sekhar, Jeffrey C. Rathmell, W. Kimryn Rathmell & Naira Baregamian. (2021) Integrative computational immunogenomic profiling of cortisol‐secreting adrenocortical carcinoma. Journal of Cellular and Molecular Medicine 25:21, pages 10061-10072.
Crossref
Crossref
Haiyan Li, Feng Liu, Xiaoyang Wang, Menglong Li, Zhihui Li, Yongmei Xie & Yanzhi Guo. (2021) Identification of Hub lncRNAs Along With lncRNA-miRNA-mRNA Network for Effective Diagnosis and Prognosis of Papillary Thyroid Cancer. Frontiers in Pharmacology 12.
Crossref
Crossref
Ying Wang, Mengxue Yang, Mingyang Tao, Peipei Liu, Cheng Kong, Hao Li, Yingmei Chen, Xudong Yin & Xuebing Yan. (2021) Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment. International Immunopharmacology 99, pages 108031.
Crossref
Crossref
Agnese Paderi, Elisabetta Gambale, Cristina Botteri, Roberta Giorgione, Daniele Lavacchi, Marco Brugia, Francesca Mazzoni, Elisa Giommoni, Susanna Bormioli, Amedeo Amedei, Serena Pillozzi, Marco Matucci Cerinic & Lorenzo Antonuzzo. (2021) Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules 26:19, pages 5789.
Crossref
Crossref
Nicholas L Bayless, Jeffrey A Bluestone, Samantha Bucktrout, Lisa H Butterfield, Elizabeth M Jaffee, Christian A Koch, Bart O Roep, Arlene H Sharpe, William J Murphy, Alexandra-Chloé Villani & Theresa L Walunas. (2021) Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. Journal for ImmunoTherapy of Cancer 9:9, pages e002627.
Crossref
Crossref
Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Kousuke Hashimoto, Yu Miura, Ayako Shiono, Shun Shinomiya, Hisao Imai, Kunihiko Kobayashi & Hiroshi Kagamu. (2021) Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. Journal of Clinical Medicine 10:16, pages 3744.
Crossref
Crossref
Hongchuan Zhang, Xuemei Li, Xingliang Huang, Junfeng Li, Hong Ma & Rui Zeng. (2021) Impact of corticosteroid use on outcomes of non–small‐cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis. Journal of Clinical Pharmacy and Therapeutics 46:4, pages 927-935.
Crossref
Crossref
K. Rzeniewicz, J. Larkin, A.M. Menzies & S. Turajlic. (2021) Immunotherapy use outside clinical trial populations: never say never?. Annals of Oncology 32:7, pages 866-880.
Crossref
Crossref